Abbott India Ltd Share Price

Pharmaceuticals - Multinational

NSE: ABBOTINDIA Mid Cap ISIN: INE358A01014
As on 04 December 2024 at 15:47
As on 04 December 2024 at 15:47
28,850
+408.95
(1.44%)
Over 1 Month
-3.46%
Over 6 Months
9.63%
Over 1 Year
21.55%
Over 3 Years
49.71%

Abbott India Ltd Summary

Close 28,850
Open 28,572
High 28,950
Low 28,357
Volume 5,870
Net Turnover 39,60,61,056.75
52 Week High 30,521
52 Week Low 22,000
52Wk High / Low
22,000
30,521

Abbott India Ltd Key Financial Data

Market Cap (in ₹ Cr) 60,437.23
EPS 604.55
Book Value (BV) 1,656.99
Div. Yield 1.44
P/E 47.05
Price/Book Value 17.17
Delivery % 63.61
Face Value 10

Abbott India Ltd Key Ratios

P/E ratio 47.67
P/B ratio 15.48
EV to Sales 9.40
PEG Ratio 1.80
ROA 30.82
ROE 34.88
Debt-Equity 0.03
Net Profit Margin 20.45
Operating Profit Margin 28.96

Abbott India Ltd Peer Comparison

Company LTP Market Cap (in ₹ Cr)
Abbott India Ltd ₹28,443.65 ₹60,442.76
Sun Pharmaceuticals Industries Ltd ₹1,798.60 ₹4,31,544.39
Divis Laboratories Ltd ₹6,210.35 ₹1,64,865.28
Cipla Ltd ₹1,534.40 ₹1,23,920.06
Torrent Pharmaceuticals Ltd ₹3,361.60 ₹1,13,766.71
Mankind Pharma Ltd ₹2,558.95 ₹1,02,527.44

Abbott India Ltd News

Abbott launches new pneumococcal vaccine for kids

Abbott India has announced the launch of its new pneumococcal conjugate vaccine, PneumoShield 14, designed for children over six weeks of age.

28 Nov 2024

Board of Abbott India appoints director

At meeting held on 07 November 2024

07 Nov 2024

Abbott India to announce Quarterly Result

On 7 November 2024

29 Oct 2024

Abbott India director resigns

With effect from 16 October 2024

18 Oct 2024

Abbott India joins hand with Takeda Pharma to launch Vonoprazan tablets in India

Abbott India said that it has signed a non-exclusive patent license agreement with Takeda Pharmaceuticals Company to commercialize Vonoprazan, a novel molecule in the gastrointestinal therapy area, under the brand name Vonefi.

20 Sep 2024

Abbott India Ltd Financials

Profit and Loss

Particulars (in ₹ Cr.) FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Total Revenue 6,097.18 5,502.88 4,996.48 4,390.92 4,207.53
Total Expenses 4,479.43 4,229.06 3,916.75 3,464.97 3,404.84
Profit Before Tax 1,617.75 1,273.82 1,079.73 925.95 802.69
Profit After Tax 1,201.22 949.41 798.70 690.69 592.93
Operating Profit after Depreciation 1,630.20 1,289.81 1,098.83 944.23 811.22

Balance Sheet

Particulars (in ₹ Cr.) FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Fixed Assets 224.94 236.91 271 250.78 269.83
Total Non Current Assets 1,947.65 1,530.40 371.08 353.04 342.21
Total Current Assets 3,245.84 3,025.11 3,853.04 3,487.41 3,204.64
TOTAL ASSETS 5,193.49 4,555.51 4,224.12 3,840.45 3,546.85
Total Shareholder's Fund 3,698.89 3,188.54 2,819.79 2,602.16 2,431.71

Cash Flow

Particulars (in ₹ Cr.) FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Net Cash from Operating Activities 1,212.81 893.39 947.66 726.74 626.11
Net Cash used in Investing Activities -416.03 -147.71 -395.84 -71.82 -401.19
Net Cash used in Financing Activities -744.71 -638.72 -637.38 -581.79 -216.79

Abbott India Ltd Corporate Actions

Abbott India Ltd

₹410/Share

Announcement Date 19 Jul 2024
Record Date 19 Jul 2024
Div Yield 4100%

About Abbott India Ltd

Abbott India Limited is a leading healthcare company. It offers a diverse range of diagnostics solutions and medical devices. The company also offers nutritional products and established pharmaceuticals. Established in 1910, Abbott India has a rich history of many decades in the healthcare sector. The company’s headquarters are located in Mumbai, Maharashtra, India.

The company is a subsidiary of Abbott Laboratories, an American healthcare giant. Abbott India benefits from a global network of expertise and innovation. The company provides products across various therapeutic categories. This includes women’s health and gastroenterology. It also includes cardiology, metabolic disorders, and primary care. Its main offerings include diagnostics solutions and medical devices. Along with that, it offers nutritional products and a range of pharmaceuticals.

It is a significant player in the healthcare sector. It holds a considerable position in the Indian healthcare market. Its success is driven by its commitment to quality and innovation. Abbott Laboratories, the parent company, holds a significant shareholding in Abbott India at 74.99%. This fact underscores the strategic importance of the Indian market to its global operations.
Here are the primary promoters of the company:
  • Munir Shaikh
  • Swati Dalal
  • Kaiyomarz Marfatia
  • Ambati Venu
  • Sabina Ewing

The registered office of Abbott India is located in Mumbai, Maharashtra. The registrar of the company isKFin Technologies Ltd. The management team includes experienced professionals guided by a dedicated Board of Directors. The team ensures robust governance and strategic direction. Abbott India continues to make significant strides in the healthcare industry. It has been contributing to improved health outcomes for millions of people in India.

Background of the Company

Abbott India Limited was established in 1910. It is one of the oldest and most respected healthcare companies in India. Headquartered in Mumbai, Maharashtra, Abbott India is a subsidiary of Abbott Laboratories, an American healthcare giant. Over the past many years, Abbott India has been dedicated to improving health and well-being. They do this through diverse science-based nutritional products and diagnostic tools. It also provides branded generic pharmaceuticals, and diabetes and vascular devices.

The company’s journey began with a commitment to providing high-quality healthcare solutions to the Indian market. Abbott India has grown significantly over the years, becoming a key player in the Indian healthcare industry. The company offers products across various therapeutic categories. This includes women’s health, gastroenterology and cardiology. It also provides products for metabolic disorders and primary care. Its main products include diagnostics solutions and medical devices. The list also includes nutritional products and a range of pharmaceuticals.

Abbott India’s mission is to help people live healthier lives by providing reliable and innovative healthcare solutions. The company’s products are known for their quality and efficacy. They play a crucial role in improving health outcomes for millions of people in India. Abbott India’s commitment to excellence is reflected in its robust product development. It is also evident in the company’s manufacturing, sales, and customer service processes.

A dedicated Board of Directors guides the company’s leadership team. They ensure that Abbott India continues to uphold its high standards of quality and innovation. The management team includes experienced professionals who are passionate about making a positive impact on healthcare in India.

Abbott India’s registered office is located at Sion Trombay Road, Mumbai, Maharashtra 4000714. Abbott India Limited was incorporated initially as Boots Pure Drug Company (India) Limited on August 22, 1944. It has a rich history of many decades. The company underwent several name changes, becoming The Boots Company (India) Limited in 1971. It finally adopted its current name, Abbott India Limited, on July 1, 2002. Abbott India is a subsidiary of Abbott Laboratories, an American healthcare giant. It is headquartered in Mumbai, Maharashtra.

Over the years, Abbott India has expanded its product portfolio to include diagnostics solutions, medical devices and nutritional products. The portfolio also includes pharmaceuticals across various therapeutic categories. The company’s commitment to quality and innovation has made it a trusted name in the Indian healthcare market. Abbott India’s extensive research and development efforts ensure that it stays at the forefront of medical advancements. It is continually improving its offerings to serve the healthcare needs of the community better.

A dedicated Board of Directors leads Abbott India’s leadership team. They play a crucial role in guiding the company’s strategic direction and maintaining its high standards. The management team comprises experienced professionals who are passionate about making a positive impact on healthcare in India. Their collective expertise and commitment to excellence drive Abbott India’s success and growth. Abbott India continues to be a leading force in the Indian healthcare industry. It is dedicated to improving health outcomes and enhancing the quality of life for millions of people.

Abbott India Limited has a rich history of many years, marked by its commitment to providing high-quality healthcare solutions. As a subsidiary of Abbott Laboratories, the company continues to play a vital role in the Indian healthcare market. It continues to contribute to improved health outcomes and well-being for millions of people.

FAQ’s

What is the share price of Abbott India Ltd today?

Abbott India Ltd share price as on 4 Dec 2024 is ₹28850

What is the Market Cap of Abbott India Ltd?

The market cap of Abbott India Ltd stock is ₹60,437.23 Cr.

What is the PE Ratio of Abbott India Ltd?

The Price to Earnings (P/E) Ratio of Abbott India Ltd is 47.67

What is the PB Ratio of Abbott India Ltd?

The Price to Book (P/B) Ratio of Abbott India Ltd is 15.48

What is the 52 week high of Abbott India Ltd Share Price?

The 52 week high of Abbott India Ltd share price stands at ₹30,521

What is the 52 week low of Abbott India Ltd Share Price?

The 52 week low of Abbott India Ltd share price stands at ₹22,000

Get started with us today and
start building your wealth journey